Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents

Eichenfield, Lawrence F.; Lucky, Anne W.; Boguniewiczc, Mark; Langley, Richard; Cherille, Robert; Marshalle, Katharine; Bushe, Christopher; Graeber, Michael

doi:10.1067/mjd.2002.122187

Cited by 323 publications

(320 citation statements)

References 24 publications

Supporting

Mentioning

294

Contrasting

Unclassified

Order By: Relevance

“…They inhibit T-cell activation and the release of numerous inflammatory cytokines 4 . They are anti-inflammatory medications that might replace steroids for the topical treatment of many inflammatory skin diseases, including atopic dermatitis, contact dermatitis, pyoderma gangrenosum, psoriasis, alopecia areata, Behcet's disease, vitiligo, and lichen sclerosus, without having atrophogenic potential or risking other steroid-specific side effects [4][5][6][7][8][9][10] .…”

Section: Introductionmentioning

confidence: 99%

Four Cases of Facial Discoid Lupus Erythematosus Successfully Treated with Topical Pimecrolimus or Tacrolimus

et al. 2010

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Four Cases of Facial Discoid Lupus Erythematosus Successfully Treated with Topical Pimecrolimus or Tacrolimus

et al. 2010

View full text Add to dashboard Cite

“…Bizim çal›flmam›zda, 6 haftal›k %1 pimekrolimus krem uygulamas› sonunda tedavi baflar›s› %58,6 olarak bulunmufltur. Bu baflar› oran›, Eichenfield ve arkadafllar› taraf›n-dan yap›lan çal›flmadaki baflar› oran›na oldukça yak›nd›r 22 . Ashcroft ve arkadafllar›n›n 2005 y›l›nda yapt›¤›, pimekrolimus ve takrolimusun etkinlik ve tolerabilitesini de¤erlendi-ren, 25 kontrollü çal›flmay› içeren bir metaanalizde %1 pimekrolimus krem ile kontrol grubunun karfl›laflt›r›ld›¤›, toplam 783 hastan›n kat›ld›¤› 4 çal›flmada, hastalar›n 3 hafta sonunda tam veya tama yak›n iyileflmesi de¤erlendirilmifltir 14,[22][23][24][25] .…”

Section: Tart›flmaunclassified

“…Bu ça-l›flmalar›n sonucunda 3. haftada pimekrolimus, kontrol grubuna göre belirgin olarak daha etkili bulunmufltur. Çal›flma-lar›n ikisinde, pimekrolimusun 6 hafta sonunda da kontrol grubuna göre belirgin olarak daha etkili oldu¤u bildirilmifltir 22,23 . Bizim çal›flmam›zda da tedavinin ilerleyen haftalar›n-da baflar› oran› artm›flt›r ve bu art›fl istatistiksel olarak anlaml› bulunmufltur (4 ve 6'nc› haftalar için p=0,005, di¤er haftalar için p<0,0001).…”

Section: Tart›flmaunclassified

Efficacy of Pimecrolimus 1% Cream in Various Clinical Forms of Atopic Dermatitis

İkizler¹,

Karabacak²,

Karabudak³

et al. 2010

turkderm

View full text Add to dashboard Cite

ÖzetAmaç: Atopik dermatit bilindi¤i gibi farkl› klinik tiplerde karfl›m›za ç›kar. Bu deneysel çal›flman›n temel amac›, atopik dermatitin bu tipleri aras›nda pimekrolimusun etkinli¤ini karfl›laflt›rmakt›r. Gereç ve Yöntem: Çal›flmaya 2-38 yafllar› aras›nda, 50'si erkek, 20'si kad›n, toplam 70 hasta al›nd›. Hastalar›n 22'si (%31,4) çocuktu (2-10 yafl). Hastalarda, solunum yolu allerjisi, total IgE yüksekli¤i, deri "prick" test pozitifli¤i ve tetikleyici allerjenler araflt›r›ld›. Hastalar Wüthrich s›n›flamas›na göre, "mikst", "pür intrinsik" ve "pür ekstrinsik" olarak s›n›fland›r›ld›. Hastalara 6 hafta boyunca günde iki kez %1 pimekrolimus krem tedavisi uyguland› ve hastalar SCORAD indeksi kullan›larak de¤erlendirildi. Bulgular: Sonuç olarak hastalar›n %58,6's›nda (n=41) tedavi baflar›l›, %4,3'ünde (n=3) tedavi k›smen baflar›l›, %37,1'inde (n=26) tedavi baflar›s›z bulundu. 35 hastada tam remisyon elde edildi. Tedavi öncesi ve sonras›ndaki SCORAD de¤erleri aras›ndaki fark, istatistiksel olarak anlaml› bulundu (p<0,0001). Sonuç: Çal›flmada, mikst, pür intrinsik ve pür ekstrinsik atopik dermatit tipleri aras›nda pimekrolimus etkinli¤i karfl›laflt›r›l-d›¤›nda, pür intrinsik tipte pimekrolimus daha etkili bulunmas›na ra¤men bu durum istatistiksel olarak anlaml› de¤ildi (p=0,75). Yine, pimekrolimus etkinli¤i aç›s›ndan, hafif ve orta fliddetli atopik dermatit hastalar› aras›nda, istatistiksel olarak anlaml› bir fark saptanmad›. (p=0,107) Ayr›ca, bu çal›flmada optimum tedavi süresinin eriflkinlerde yaklafl›k 6 hafta, çocuklarda ise 4 hafta oldu¤u kan›s›na var›ld›. (Türkderm 2010; 44: 83-7) Anahtar Kelimeler: Atopik dermatit, tedavi, pimekrolimus, etkinlik SummaryBackground and Design: Atopic dermatitis shows some different clinical appearances.The main aim of this experimental study is to compare the efficacy of pimecrolimus among these clinical subgoups of atopic dermatitis. Material and Method: A total of 70 patients, 50 male and 20 female, aged between 2-38 years were included in the study. Twenty-two patients (%31.4) were pediatric (2-10 years). Patients were investigated in regard to high levels of total IgE, airway allergy, positive skin prick test and triggering allergens. Patients were classified as: mixed, pure intrinsic and pure extrinsic according to Wüthrich classification. Pimecrolimus 1% cream was applied to the patients twice daily for 6 weeks and patients were evaluated with SCORAD index before and after treatment. Results: FAs a result, 58.6% of the patients (n=41) had a successful therapy with pimecrolimus while 4.3% (n=3) had partially successful. Thirty-five patients achieved full remission. The difference between the SCORADs before and after the treatment was found to be statistically significant (p<0.0001). Conclusion: In this study, efficacy of pimecrolimus was compared to mixed, pure intrinsic and pure extrinsic types of atopic dermatitis. Although pimecrolimus was more effective in the pure intrinsic type, it was not statistically significant (p=0,75). There was also an insignificant difference b...

show abstract

“…34,35 Staphylococcus aureus is a common skin pathogen. It also colonizes the nipple 36 and is strongly associated with nipple fissures. 37 Furthermore, many patients with atopic dermatitis have colonization by Staphylococcus aureus.…”

Section: Treatmentmentioning

confidence: 99%

Nipple and Areolar Eczema in the Breastfeeding Woman

Barankin

Gross

2004

JCMS

View full text Add to dashboard Cite

Eczema of the nipple and areola can occasionally develop in the breastfeeding patient and is associated with sore, burning, and painful areolae and nipples. Management includes elimination of any precipitating allergens and irritants and the judicious use of appropriate topical corticosteroid preparations. Patients must also be offered effective pain control and support. The proper diagnosis and management of eczema of the nipple and areola in breastfeeding patients will prevent premature and iatrogenic weaning.

show abstract

Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents

Cited by 323 publications

References 24 publications

Four Cases of Facial Discoid Lupus Erythematosus Successfully Treated with Topical Pimecrolimus or Tacrolimus

Four Cases of Facial Discoid Lupus Erythematosus Successfully Treated with Topical Pimecrolimus or Tacrolimus

Efficacy of Pimecrolimus 1% Cream in Various Clinical Forms of Atopic Dermatitis

Nipple and Areolar Eczema in the Breastfeeding Woman

Contact Info

Product

Resources

About